Business
Erasca Announces Poster Presentation at the 2023 AACR Annual Meeting
Poster will feature preliminary Phase 1 dose escalation data for potential best-in-class SHP2 inhibitor ERAS-601 in combination with cetuximab SAN DIEGO,
About this update from Erasca, Inc.
[{"type":"text","content":"Poster will feature preliminary Phase 1 dose escalation data for potential best-in-class SHP2 inhibitor ERAS-601 in combination with cetuximab\nSAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the company will present a poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 14-19, 2023, in Orlando, Florida. The abstract will be available on the AACR meeting website. The poster will be available online at Erasca.com/science/presentations following the presentation. Poster Presentation Details Abstract CT184 – Preliminary dose escalation results of ERAS-601 in combination with cetuximab in FLAGSHP-1: A Phase 1 study of ERAS-601, a potent and selective SHP2 inhibitor, in patients with previously treated advanced or metastatic solid tumors Date/Time: Tuesday, April 18, 2023, 9:00 AM - 12:30 PM ETSession: First-in-Human Phase I Clinical Trials 2Presenter: Dr. Meredith McKean, Sarah Cannon Research Institute at Tennessee OncologyLocation: Orange County Convention Center, Poster Section 45, Poster Board 16 About ErascaAt Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of cancer. We have assembled what we believe to be the deepest RAS/MAPK pathway-focused pipeline in the industry. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer. Cautionary Note Regarding Forward-Looking Statements Erasca cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and ...